How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update

Revue neurologique
A MaaroufJ Pelletier

Abstract

In 1993, the US Food and Drug Administration (FDA) approved the first drug specifically for treating multiple sclerosis (MS). More than two decades later, a dozen such treatments are now available. Of these, four are considered second-line treatments for use in escalation strategies and two new drugs are currently undergoing accreditation procedures. Soon, they will provide clinicians with a range of six effective disease-modifying treatments (DMTs) to thwart the inflammatory processes in MS patients with active disease. However, while such a large number of DMTs for MS can help to control early inflammation, any decisions to be made by clinicians have also been made substantially more complex. This complexity is increased by the lack of head-to-head studies comparing these second-line therapies and the benefit-risk profiles for each of these drugs, which are likely to vary among patients. Ultimately, good awareness of the benefits and, more important, the risks of each MS DMT is crucial for the effective management of inflammation in MS.

References

Jan 29, 1998·The New England Journal of Medicine·B D TrappL Bö
Dec 31, 2002·Lancet·Hans-Peter HartungUNKNOWN Mitoxantrone in Multiple Sclerosis Study Group (MIMS)
Jan 3, 2003·The New England Journal of Medicine·David H MillerUNKNOWN International Natalizumab Multiple Sclerosis Trial Group
Jun 18, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·M ZareiJ Hodges
Nov 20, 2004·Science·Gwendolyn F ElphickWalter J Atwood
Sep 10, 2005·Journal of Neurology·Valentina TomassiniCarlo Pozzilli
Jan 18, 2006·Brain : a Journal of Neurology·Christian Confavreux, Sandra Vukusic
Jan 26, 2006·Neurology·Helen TremlettVirginia Devonshire
Mar 3, 2006·The New England Journal of Medicine·Chris H PolmanUNKNOWN AFFIRM Investigators
Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
May 1, 2007·Multiple Sclerosis : Clinical and Laboratory Research·E CoccoMg Marrosu
Sep 1, 2007·Neurology·P A CalabresiUNKNOWN AFFIRM and SENTINEL Investigators
Feb 15, 2008·The New England Journal of Medicine·Stephen L HauserUNKNOWN HERMES Trial Group
Apr 22, 2008·Multiple Sclerosis : Clinical and Laboratory Research·T VollmerD L Arnold
Oct 24, 2008·The New England Journal of Medicine·Alasdair J ColesP K Tandon
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Winnie YeoPaul K S Chan
Mar 4, 2009·Neurology·A D GoodmanUNKNOWN GLANCE Investigators
Mar 25, 2009·Journal of Neurology·Michael HutchinsonUNKNOWN AFFIRM and SENTINEL Investigators
Jun 23, 2009·Multiple Sclerosis : Clinical and Laboratory Research·J RíoX Montalbán
Jan 22, 2010·The New England Journal of Medicine·Ludwig KapposUNKNOWN FREEDOMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Jeffrey A CohenUNKNOWN TRANSFORMS Study Group
Jan 22, 2010·The New England Journal of Medicine·Gavin GiovannoniUNKNOWN CLARITY Study Group
Apr 16, 2010·Journal of Neurology, Neurosurgery, and Psychiatry·Bertrand AudoinJean-Philippe Ranjeva
Apr 29, 2010·Brain : a Journal of Neurology·Emmanuelle LerayGilles Edan
Jun 11, 2010·Brain : a Journal of Neurology·Antonio ScalfariGeorge C Ebers
Sep 10, 2010·Journal of Neurology, Neurosurgery, and Psychiatry·Carsten LukasHugo Vrenken
Nov 16, 2010·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Theodoros KelesidisSotirios Tsiodras
Nov 26, 2010·Neurology·M TintoreX Montalban
Feb 18, 2011·Multiple Sclerosis : Clinical and Laboratory Research·E Le PageUNKNOWN French Mitoxantrone Safety Group
Mar 26, 2011·Journal of Neurology, Neurosurgery, and Psychiatry·G EdanUNKNOWN French–Italian Mitoxantrone Interferon-beta-1b Trial Group
Jul 16, 2011·Multiple Sclerosis : Clinical and Laboratory Research·MariaPia SormaniNicola De Stefano
May 18, 2012·The New England Journal of Medicine·Gary BloomgrenCarmen Bozic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here